Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients

• ClinicalTrials.gov Identifier: NCT00369278
• Recruitment Status: Completed
• First Posted: August 29, 2006
• Results First Posted: January 12, 2011
• Last Update Posted: March 29, 2011
• Sponsor: Novartis Pharmaceuticals
• Information provided by: Novartis

Study Description

Brief Summary:

This study will assess the association of an initially intensified dosing regimen of enteric-coated mycophenolate sodium (EC-MPS) during the first 6 weeks post renal transplantation with acute rejections relative to the rapid achievement of an MPA (mycophenolic acid) exposure of ≥ 40 mg*h/L compared to a standard dosing regimen of EC-MPS. Additionally, this study will assess safety and tolerability of the intensified dosing regimen of EC-MPS. This study will be conducted in 2 stages (Stage I and Stage II).

Condition or disease	Intervention/treatment	Phase
Renal Transplantation	Drug: Enteric-coated mycophenolate sodium (EC-MPS)	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 128 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating an Intensified Enteric-coated Mycophenolate Sodium (EC-MPS) Dosing Regimen in Comparison to a Standard Dosing Regimen of EC-MPS in Combination With Cyclosporin Microemulsion and Corticosteroids in de Novo Renal Transplant Patients
• Study Start Date: June 2006
• Actual Primary Completion Date: December 2008
• Actual Study Completion Date: December 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: Intensified Mycophenolate sodium; Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.	Drug: Enteric-coated mycophenolate sodium (EC-MPS); Tablets for oral administration; Other Name: myfortic
Active Comparator: Standard Mycophenolate sodium; Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.	Drug: Enteric-coated mycophenolate sodium (EC-MPS); Tablets for oral administration; Other Name: myfortic

Outcome Measures

Primary Outcome Measures :

1. Time to First Occurrence of a Mycophenolic Acid (MPA) Plasma Concentration of ≥ 40 mg*h/L [ Time Frame: Assessed on day 3, 10, 21, 42, 56 and 84 ]
   Non-compartmental MPA pharmacokinetic parameters were derived from individual plasma concentration-time profiles using WinNonLin 5.2 software. The areas under the curve were calculated by means of the linear trapezoidal rule.
2. Time to First Occurrence of Any Treatment Failure During the First 6 Months Post-treatment or at Month 6 Post-treatment [ Time Frame: 6 months ]
   Median time to first occurrence of treatment failure was not reached in this study.
3. Number of Participants With Any Treatment Failure [ Time Frame: 6 months ]
   Treatment failures were defined as a composite endpoint of biopsy proven acute rejection (BPAR), graft loss, and death, loss to follow up and discontinuations from study drug treatment due to lack of efficacy or toxicity (at least one condition must be present) during the first 6 months or until final assessment. Any participants who were suspected of having acute rejection episodes had biopsies performed to prove whether a rejection had occurred. Graft loss was considered as the day the patient started dialysis and was not able to subsequently be removed or the day of graft nephrectomy.

Secondary Outcome Measures :

1. Number of Participants With Single Treatment Failures [ Time Frame: 6 months ]

   Rates for all individual components of the primary endpoint 'treatment failure' until day 180:

   • Acute rejection diagnosed by biopsy (BPAR)
   • graft loss
   • death
   • loss to follow up
   • discontinuation from study drug due to lack of efficacy or toxicity (adverse events, every adverse event had to be interpreted as toxicity)
   • conversion to another dosing regimen (conversion to tacrolimus, prograf, etc.)
2. Rates of Events for Treated Acute Rejection, Death, Graft Loss, or Loss to Follow up on Day 28, Day 84, and Day 180 [ Time Frame: 6 months ]
   Due to a small number of events, median time to <event> was not reached.
3. Time to "Event" for the Composite Endpoint as Well as All Individual Components of That Endpoint "Treatment Failure" Including Clinical Rejections [ Time Frame: 6 months ]
   Due to a small number of events, median time to <event> was not reached.
4. Renal Function as Measured by Serum Creatinine [ Time Frame: 6 months ]
5. Renal Function as Measured by Glomerular Filtration Rate (GFR) [ Time Frame: 6 months ]

   The Glomerular Filtration Rate (GFR) was calculated using the following formulas:

   • Cockcroft-Gault formula: calculation using the participant's age, gender, weight, and serum creatinine levels.
   • MDRD formula: calculation using the participant's age, gender, serum creatinine, urea nitrogen, and albumin levels.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All

Criteria

Inclusion criteria

1. Recipients of de novo cadaveric, living unrelated or living related kidney transplants
2. Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.
3. Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.

Exclusion criteria

1. More than one previous renal transplantation
2. Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation)
3. Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney
4. Patients receiving a kidney from a non-heart beating donor
5. Patients who are recipients of A-B-O incompatible transplants

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Locations

Germany

Novartis Investigational Site

Various Cities, Germany

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

• Study Director: Novartis; Novartis

More Information

• Responsible Party: External Affairs, Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT00369278
• Other Study ID Numbers: CERL080ADE12
• First Posted: August 29, 2006
• Results First Posted: January 12, 2011
• Last Update Posted: March 29, 2011
• Last Verified: March 2011

Keywords provided by Novartis:

Renal transplantation, mycophenolate

Additional relevant MeSH terms:

Mycophenolic Acid; Antibiotics, Antineoplastic; Antineoplastic Agents; Antibiotics, Antitubercular; Antitubercular Agents; Anti-Bacterial Agents; Anti-Infective Agents; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action